Think tank and survey results inform current DCT landscape.
Two recent activities by ACRP offers insights into industry’s views on decentralized clinical trials (DCT). In a think tank convened in October, participants from a variety of clinical trial stakeholder groups, offered that lack of clarity around regulatory requirements is the leading barrier to adopting DCTs at the site level, as well as a lack of budget flexibility and the challenges of managing third-party vendors. Additionally, survey results released by ACRP revealed that on a site-level, DCT technology utilization lags behind other trial technologies, sites that use DCT elements spend more time on trial delivery activities, and personnel perceptions of DCT elements strongly influence DCT acceptance.
Read more information on these ACRP resources.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
FDA Grants Priority Review to Merck’s sBLA for Winrevair After Early Success in ZENITH PAH Trial
July 2nd 2025Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% reduction in major morbidity and mortality events in patients with pulmonary arterial hypertension.